MindMed to be Included in Russell 2000® and Russell 3000® Indexes
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
Optimi Health preparing to export 160 doses of MDMA and psilocybin under Australia's Authorized Prescriber Scheme.
MindMed to Participate in June Conferences
MindMed to Participate at May Investor Conferences
MindMed Reports First Quarter 2024 Financial Results and Business Updates
The month of May is Mental Health Awareness Month, and an appropriate time to shine a spotlight on a mental health disorder that has been underserved and underacknowledged for too long.
MindMed to Host Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Business Update
MindMed to Present at Upcoming May Medical Conferences